Genomic research is constantly pushing the boundaries of our understanding, and breakthrough technologies are the key to unlocking new scientific insights. The DNBSEQ-T7 represents a significant leap forward in our ability to read and understand genetic information with unprecedented precision and efficiency.

What makes DNA Nanoball Technology Revolutionary?

Genetic sequencing is fundamentally about capturing the most accurate snapshot of DNA possible. The DNBSEQ-T7 represents a significant advancement in how we approach this critical scientific challenge through its innovative DNA Nanoball technology.

In conventional bridge amplification, DNA fragments are copied by attaching them to a surface and creating multiple copies through repeated synthesis cycles. During this process, the genetic material is denatured multiple times with each copying cycle carrying potential for errors. This replication process also has limitations like some regions being difficult to copy uniformly, sections being over- or under-represented, and fragments from different DNA molecules can merge incorrectly.

The rolling circle amplification (RCR) used in DNB technology works differently.  An enzyme makes a small cut in a strain of circular DNA, grabs onto the strain, and creates a repeating strand based on the original material turning into a compact nanoball of DNA aka DNB. This amplification process eliminates the potential for errors found in bridge amplification such as index hopping while also severely reducing the chances of indel or clonal errors.

What does the performance and capabilities of the DNBSEQ-T7 look like?

The platform’s performance is nothing short of remarkable with:

• The capacity to sequence 12 human genomes on a single 300-cycle flow cell within 24 hours
• The ability to operate four flow cells concurrently
• Flexible configuration options to meet diverse research needs

The DNBSEQ-T7 also provides researchers with the ability to combine next-generation sequencing with spatial transcriptomics also referred to as Stereo-Seq.

What is Stereo-Seq?

Stereo-seq is spatial transcriptomics technology created by Complete Genomics. Stereo-seq combines next-generation sequencing with spatial transcriptomics that allows researchers to map the spatial distribution of RNA transcripts within tissues. Stereo-seq offers insights into gene expression patterns with subcellular resolution. This technology, which was highlighted on the front cover of Cell in 2022, provides researchers with a new microscopic window in which to study development of diseases like cancer and further our understanding of cellular communication.

Where does the HTSF come in?

As we expand our technological capabilities, we remain committed to supporting innovative research through collaborative partnerships. The integration of the DNBSEQ-T7 into our facility enhances our ability to serve diverse research objectives while maintaining competitive pricing and rapid turnaround times.

Our current service configurations for the DNBSEQ-T7 include:

• 200-cycle configuration: Approximately 1 TB of data (5 billion clusters) at $4,500 ($4.5/Gb)
• 300-cycle configuration: Approximately 1.7 TB of data (8.5 billion clusters) at $5,000 ($5/Gb)

We’re genuinely excited to explore how DNBSEQ-T7 could enhance your research initiatives. Our team of experienced genomics specialists is eager to discuss your specific research questions and help determine how this platform’s capabilities could accelerate your discoveries. Whether you’re planning to scale up existing protocols or venture into new experimental territories, we’re here to support your scientific journey with both technical expertise and collaborative spirit.

This is a presentation on the comparison of the same series of libraries run on both the HS2500 and the Novaseq. These were TruSeq stranded mRNA. Pools of 4 libraries were run on the HiSeq 2500/ paired end/ 50x. The same pools were then pooled into larger pools (pools of pools) to be run on the NovaseqS1/ PE/50x to achieve similar data coverage. This presentation covered the differences in the platforms, the data yielded from each and lessons learned.

By creating new mammary tumor models, we find that tumor mutation burden and specific immune cells are associated with response.

The core generated both single cell and bulk RNA-seq gene expression data to help this team of Lineberger researchers identify mechanisms mediating responses to immune checkpoint inhibitors using mouse models of triple-negative breast cancer.

Hollern et al. Cell. Volume 179, Issue 5, 14 November 2019, Pages 1191-1206.e21

Immune checkpoint inhibitors (ICIs) have improved patient outcomes in human cancers. In many solid tumors, tumor mutation burden (TMB) and, as a result of high TMB, neoantigen load are biomarkers for therapeutic benefit. In triple-negative breast cancer (TNBC), immune cells identified by pathology or by genomic signatures indicate a favorable prognosis and chemotherapy efficacy is more likely in tumors with immune infiltrates. In this project, the core helped developed a rich resource of single-cell RNA-seq and bulk mRNA-seq data of immunotherapy-treated and non-treated tumors from sensitive and resistant murine models. Using this, the research team uncover that immune checkpoint therapy induces T follicular helper cell activation of B cells to facilitate the anti-tumor response in these models. They also showed that B cell activation of T cells and the generation of antibody are key to immunotherapy response and propose a new biomarker for immune checkpoint therapy. This work presents resources of new preclinical models of breast cancer with large mRNA-seq and single-cell RNA-seq datasets annotated for sensitivity to therapy and uncovers new components of response to immune checkpoint inhibitors.

Jan 30, 2014 – The HTSF’s website is now hosted by ºÚÁÏÍø’s School of Medicine Web System.

Starting in early February, the HTSF’s website is migrating to the ºÚÁÏÍø . The new website incorporates a number of new features that will allow the HTSF to become more closely integrated with the ºÚÁÏÍø while making our genomic sequencing services more accessible to researchers from other departments and research facilities.